SGLT2 inhibitors, initially developed for glycemic control in type 2 diabetes, have demonstrated broad renoprotective benefits across diverse chronic kidney disease (CKD) populations, including IgAN. The gene discussed is SLC5A2; the disease is chronic kidney disease.